BR112015002541A2 - composto, composição farmacêutica, uso de um composto, e, método para tratamento de hcv em um paciente. - Google Patents
composto, composição farmacêutica, uso de um composto, e, método para tratamento de hcv em um paciente.Info
- Publication number
- BR112015002541A2 BR112015002541A2 BR112015002541A BR112015002541A BR112015002541A2 BR 112015002541 A2 BR112015002541 A2 BR 112015002541A2 BR 112015002541 A BR112015002541 A BR 112015002541A BR 112015002541 A BR112015002541 A BR 112015002541A BR 112015002541 A2 BR112015002541 A2 BR 112015002541A2
- Authority
- BR
- Brazil
- Prior art keywords
- compound
- patient
- pharmaceutical composition
- treating hcv
- hcv
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/12—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains three hetero rings
- C07D491/20—Spiro-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/08—Tripeptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/438—The ring being spiro-condensed with carbocyclic or heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4747—Quinolines; Isoquinolines spiro-condensed
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/06—Tripeptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D419/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen, oxygen, and sulfur atoms as the only ring hetero atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/10—Spiro-condensed systems
- C07D491/107—Spiro-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/22—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains four or more hetero rings
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261680889P | 2012-08-08 | 2012-08-08 | |
| US201261739345P | 2012-12-19 | 2012-12-19 | |
| PCT/US2013/053725 WO2014025736A1 (en) | 2012-08-08 | 2013-08-06 | Hcv ns3 protease inhibitors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR112015002541A2 true BR112015002541A2 (pt) | 2017-12-05 |
Family
ID=48980370
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112015002541A BR112015002541A2 (pt) | 2012-08-08 | 2013-08-06 | composto, composição farmacêutica, uso de um composto, e, método para tratamento de hcv em um paciente. |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US8987195B2 (pt) |
| EP (1) | EP2882754B1 (pt) |
| JP (1) | JP2015529661A (pt) |
| KR (1) | KR20150037996A (pt) |
| CN (1) | CN104718211A (pt) |
| AR (1) | AR091976A1 (pt) |
| AU (1) | AU2013299807A1 (pt) |
| BR (1) | BR112015002541A2 (pt) |
| CA (1) | CA2880993A1 (pt) |
| MX (1) | MX2015001765A (pt) |
| RU (1) | RU2015107738A (pt) |
| TW (1) | TW201408669A (pt) |
| WO (1) | WO2014025736A1 (pt) |
Families Citing this family (33)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9151646B2 (en) | 2011-12-21 | 2015-10-06 | Deka Products Limited Partnership | System, method, and apparatus for monitoring, regulating, or controlling fluid flow |
| US9372486B2 (en) | 2011-12-21 | 2016-06-21 | Deka Products Limited Partnership | System, method, and apparatus for monitoring, regulating, or controlling fluid flow |
| US9435455B2 (en) | 2011-12-21 | 2016-09-06 | Deka Products Limited Partnership | System, method, and apparatus for monitoring, regulating, or controlling fluid flow |
| US9746094B2 (en) | 2011-12-21 | 2017-08-29 | Deka Products Limited Partnership | Flow meter having a background pattern with first and second portions |
| US10228683B2 (en) | 2011-12-21 | 2019-03-12 | Deka Products Limited Partnership | System, method, and apparatus for monitoring, regulating, or controlling fluid flow |
| US9724465B2 (en) | 2011-12-21 | 2017-08-08 | Deka Products Limited Partnership | Flow meter |
| US9746093B2 (en) | 2011-12-21 | 2017-08-29 | Deka Products Limited Partnership | Flow meter and related system and apparatus |
| US10488848B2 (en) | 2011-12-21 | 2019-11-26 | Deka Products Limited Partnership | System, method, and apparatus for monitoring, regulating, or controlling fluid flow |
| MX360452B (es) | 2012-10-19 | 2018-11-01 | Bristol Myers Squibb Co | Inhibidores del virus de la hepatitis c. |
| US9598433B2 (en) | 2012-11-02 | 2017-03-21 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
| WO2014071007A1 (en) | 2012-11-02 | 2014-05-08 | Bristol-Myers Squibb Company | Hepatitis c virus inhibitors |
| US9643999B2 (en) | 2012-11-02 | 2017-05-09 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
| WO2014070974A1 (en) | 2012-11-05 | 2014-05-08 | Bristol-Myers Squibb Company | Hepatitis c virus inhibitors |
| US9759343B2 (en) | 2012-12-21 | 2017-09-12 | Deka Products Limited Partnership | Flow meter using a dynamic background image |
| WO2014137869A1 (en) | 2013-03-07 | 2014-09-12 | Bristol-Myers Squibb Company | Hepatitis c virus inhibitors |
| USD752209S1 (en) | 2013-11-06 | 2016-03-22 | Deka Products Limited Partnership | Apparatus to control fluid flow through a tube |
| USD751690S1 (en) | 2013-11-06 | 2016-03-15 | Deka Products Limited Partnership | Apparatus to control fluid flow through a tube |
| USD749206S1 (en) | 2013-11-06 | 2016-02-09 | Deka Products Limited Partnership | Apparatus to control fluid flow through a tube |
| USD751689S1 (en) | 2013-11-06 | 2016-03-15 | Deka Products Limited Partnership | Apparatus to control fluid flow through a tube |
| USD745661S1 (en) | 2013-11-06 | 2015-12-15 | Deka Products Limited Partnership | Apparatus to control fluid flow through a tube |
| WO2016054585A1 (en) * | 2014-10-02 | 2016-04-07 | Brigham Young University | Autonomous ambient air sampling system for monitoring semi- volatile/non-volatile organic compounds |
| CN105712901B (zh) * | 2016-01-22 | 2017-07-14 | 成都柏睿泰生物科技有限公司 | 一种光学活性中间体n‑叔丁氧羰基‑2‑氨基‑8‑壬烯酸二环己胺盐的合成方法 |
| US11744935B2 (en) | 2016-01-28 | 2023-09-05 | Deka Products Limited Partnership | Apparatus for monitoring, regulating, or controlling fluid flow |
| USD905848S1 (en) | 2016-01-28 | 2020-12-22 | Deka Products Limited Partnership | Apparatus to control fluid flow through a tube |
| EP3455218A4 (en) | 2016-05-10 | 2019-12-18 | C4 Therapeutics, Inc. | C3 CARBON-BASED GLUTARIMIDE DEGRONIMERS FOR TARGET PROTEIN REDUCTION |
| WO2017197055A1 (en) | 2016-05-10 | 2017-11-16 | C4 Therapeutics, Inc. | Heterocyclic degronimers for target protein degradation |
| WO2017197036A1 (en) | 2016-05-10 | 2017-11-16 | C4 Therapeutics, Inc. | Spirocyclic degronimers for target protein degradation |
| USD854145S1 (en) | 2016-05-25 | 2019-07-16 | Deka Products Limited Partnership | Apparatus to control fluid flow through a tube |
| CN106854211A (zh) * | 2016-12-28 | 2017-06-16 | 苏州旷世骏弛生物科技有限公司 | 一种蛋白酶抑制剂的制备方法 |
| RU2650610C1 (ru) | 2017-02-28 | 2018-04-16 | Васильевич Иващенко Александр | Противовирусная композиция и способ ее применения |
| WO2021021596A1 (en) | 2019-07-26 | 2021-02-04 | Deka Products Limited Partnership | Apparatus for monitoring, regulating, or controlling fluid flow |
| USD964563S1 (en) | 2019-07-26 | 2022-09-20 | Deka Products Limited Partnership | Medical flow clamp |
| US20230042042A1 (en) * | 2019-12-17 | 2023-02-09 | Temple University-Of The Commonwealth System Of Higher Education | Unnatural amino acids and uses thereof |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2006102087A2 (en) | 2005-03-22 | 2006-09-28 | Merck & Co., Inc. | Hcv protease substrates |
| CN101228181B (zh) * | 2005-07-20 | 2013-09-18 | 默沙东公司 | Hcv ns3蛋白酶抑制剂 |
| TWI387603B (zh) * | 2005-07-20 | 2013-03-01 | Merck Sharp & Dohme | Ｈｃｖ ｎｓ３蛋白酶抑制劑 |
| AR055395A1 (es) * | 2005-08-26 | 2007-08-22 | Vertex Pharma | Compuestos inhibidores de la actividad de la serina proteasa ns3-ns4a del virus de la hepatitis c |
| US7964624B1 (en) | 2005-08-26 | 2011-06-21 | Vertex Pharmaceuticals Incorporated | Inhibitors of serine proteases |
| US20080108632A1 (en) * | 2006-11-02 | 2008-05-08 | Taigen Biotechnology Co., Ltd. | Hcv protease inhibitors |
| CN104016970A (zh) * | 2007-10-10 | 2014-09-03 | 诺华股份有限公司 | 螺环吡咯烷类与其对抗hcv和hiv感染的应用 |
| UY32099A (es) | 2008-09-11 | 2010-04-30 | Enanta Pharm Inc | Inhibidores macrocíclicos de serina proteasas de hepatitis c |
| US20110182850A1 (en) | 2009-04-10 | 2011-07-28 | Trixi Brandl | Organic compounds and their uses |
| BR112013008510A2 (pt) | 2010-10-08 | 2016-07-05 | Novartis Ag | vitamina e formulações de inibidores de sulfamida ns3 |
-
2013
- 2013-08-01 TW TW102127677A patent/TW201408669A/zh unknown
- 2013-08-02 AR ARP130102754A patent/AR091976A1/es unknown
- 2013-08-06 KR KR20157003026A patent/KR20150037996A/ko not_active Application Discontinuation
- 2013-08-06 JP JP2015526625A patent/JP2015529661A/ja active Pending
- 2013-08-06 RU RU2015107738A patent/RU2015107738A/ru unknown
- 2013-08-06 CN CN201380052285.7A patent/CN104718211A/zh active Pending
- 2013-08-06 EP EP13748245.1A patent/EP2882754B1/en active Active
- 2013-08-06 WO PCT/US2013/053725 patent/WO2014025736A1/en active Application Filing
- 2013-08-06 US US13/960,343 patent/US8987195B2/en active Active
- 2013-08-06 CA CA2880993A patent/CA2880993A1/en not_active Abandoned
- 2013-08-06 BR BR112015002541A patent/BR112015002541A2/pt not_active Application Discontinuation
- 2013-08-06 AU AU2013299807A patent/AU2013299807A1/en not_active Abandoned
- 2013-08-06 MX MX2015001765A patent/MX2015001765A/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| AU2013299807A1 (en) | 2015-02-05 |
| MX2015001765A (es) | 2015-06-03 |
| US20140057836A1 (en) | 2014-02-27 |
| JP2015529661A (ja) | 2015-10-08 |
| EP2882754B1 (en) | 2018-10-03 |
| RU2015107738A (ru) | 2016-09-27 |
| KR20150037996A (ko) | 2015-04-08 |
| US8987195B2 (en) | 2015-03-24 |
| AR091976A1 (es) | 2015-03-11 |
| TW201408669A (zh) | 2014-03-01 |
| CN104718211A (zh) | 2015-06-17 |
| CA2880993A1 (en) | 2014-02-13 |
| WO2014025736A1 (en) | 2014-02-13 |
| EP2882754A1 (en) | 2015-06-17 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR112015002541A2 (pt) | composto, composição farmacêutica, uso de um composto, e, método para tratamento de hcv em um paciente. | |
| BR112015003397A2 (pt) | composto, composição farmacêutica, uso do composto e método para tratar uma doença ou condição mediada por rorgammat em um paciente. | |
| BR112015003332A2 (pt) | composto, composição farmacêutica, uso do composto e método para tratar uma doença ou condição mediada por rorgammat em um paciente | |
| BR112015003398A2 (pt) | composto, composição farmacêutica, uso do composto e método para tratar uma doença ou condição mediada por rorgammat em um paciente | |
| HK1215378A1 (zh) | 藥物組合物、治療方法及其用途 | |
| BR112012022879A2 (pt) | composto, composição farmacêutica, uso do composto e método de tratamento | |
| BR112014023937A2 (pt) | composição farmacêutica, agente farmacêutico de combinação e método de tratamento | |
| BR112014002621A2 (pt) | anticorpo, composição farmacêutica, combinação farmacêutica, dna e método de tratamento | |
| BR112014010179A8 (pt) | composto, composição farmacêutica, uso de um composto, e, método para a profilaxia ou tratamento de um estado ou condição | |
| BR112012022878A2 (pt) | composto, composição farmacêutica, uso do compostos e método de tratamento | |
| PL2672966T3 (pl) | Kompozycja farmaceutyczna, sposoby leczenia i jej zastosowania | |
| BR112014021103A8 (pt) | anticorpo, composição farmacêutica, droga de combinação, dna, método de tratamento e uso de anticorpo | |
| BR112014010206A2 (pt) | composto, composição farmacêutica, uso de composto, e, método para a profilaxia ou tratamento de um estado ou condição de doença | |
| BR112013020352A2 (pt) | composto, composição farmacêutica, uso de um composto e método para tratar doença ou condição mediana por rorgamat num indivíduo | |
| RS61827B1 (sr) | Farmaceutska kompozicija, postupci za lečenje i njihova primena | |
| BR112012026570A2 (pt) | composto, composição farmacêutica, uso de um composto, método para o tratamento de um indíviduo e produto combinado | |
| BR112014032510A2 (pt) | composto, composição farmacêutica, método para tratar ou prevenir uma doença ou desordem, e, uso de um composto. | |
| BR112014031512A2 (pt) | composição cosmética e método para o tratamento cosmético. | |
| BR112014016736A8 (pt) | composto, composição farmacêutica, método para tratamento, uso de um composto e invenção | |
| BR112015008798A2 (pt) | método para o tratamento de plantas e uso | |
| BR112014025339A8 (pt) | método para tratamento ou prevenção ou redução de infecção do virus influenza e composição farmacêutica para o mesmo. | |
| BR112014003556A2 (pt) | método de tratamento de vírus, e, composição farmacêutica | |
| EP2924042A4 (en) | BIS-BETA-CARBOLINE COMPOUND AND METHOD OF MANUFACTURING, PHARMACEUTICAL COMPOSITION AND USE THEREOF | |
| EP2786982A4 (en) | AMINO-PROPYLENE-GLYCOL DERIVATIVES, PREPARATION METHOD, PHARMACEUTICAL COMPOSITION AND USE THEREOF | |
| BR112014012759A8 (pt) | composto, composição e método para tratamento |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B11A | Dismissal acc. art.33 of ipl - examination not requested within 36 months of filing | ||
| B11Y | Definitive dismissal acc. article 33 of ipl - extension of time limit for request of examination expired |